natgillin/translations-raw huggingface dataset:
Following administration of a single 200 mg/100 mg oral dose of 14C paritaprevir /ritonavir to humans, the parent drug was the major circulating component, accounting for approximately 90% of the plasma radioactivity.
Nakon primjene jednokratne peroralne doze 14C- paritaprevira/ritonavira od 200 mg/100 mg u ljudi, glavna cirkulirajuća komponenta bio je ishodišni spoj, koji je činio približno 90% radioaktivnosti u plazmi.
Following administration of a single 4 mg/kg or 6 mg/kg intravenous dose of daptomycin over a 30- minute period to subjects with various degrees of renal impairment, total daptomycin clearance (CL) decreased and systemic exposure (AUC) increased as renal function (creatinine clearance) decreased.
Nakon primjene jednokratne intravenske doze daptomicina od 4 mg/kg ili 6 mg/kg tijekom 30 minuta ispitanicima s različitim stupnjevima oštećenja bubrega, ukupni klirens daptomicina (CL) se smanjivao, a sustavna izloženost (AUC) se povećavala kako se pogoršavala bubrežna funkcija (smanjivao klirens kreatinina).
Following administration of a single 50 mg-dose, the AUC0- of eltrombopag was 32% to 36% lower in subjects with mild to moderate renal impairment, and 60% lower in subjects with severe renal impairment compared with healthy volunteers.
Nakon jednokratne primjene doze od 50 mg, AUC0- eltrombopaga je bila 32% do 36% niža u ispitanika s blagim do umjerenim oštećenjem bubrega, i 60% niža u ispitanika s teškim oštećenjem bubrega, u odnosu na zdrave dobrovoljce.
Following administration of a single 600 mg intravenous dose of ceftaroline fosamil, the pharmacokinetics of ceftaroline were similar between healthy elderly subjects (≥ 65 years of age), and healthy young adult subjects (18-45 years of age).
Nakon primjene jedne intravenske doze od 600 mg ceftarolinfosamila, farmakokinetika ceftarolina bila je podjednaka u zdravih starijih ispitanika (≥ 65 godina) i zdravih mladih odraslih ispitanika (18-45 godina).
Following administration of a single dose of Akynzeo, netupitant is eliminated from the body in a multi-exponential fashion, with an apparent mean elimination half-life of 88 hours in cancer patients.
Nakon primjene jedne doze Akynzea u bolesnika s rakom, netupitant se eliminira iz tijela multi- eksponencijalno, s prividnim srednjim poluvijekom eliminacije od 88 sati.
Following administration of a single dose of an oral contraceptive medicinal product (ethinylestradiol
Nakon primjene jednokratne doze oralnog kontraceptivnog lijeka (etinilestradiol
Following administration of a single dose of lesinurad to individuals with renal impairment compared to those with normal renal function lesinurad Cmax and AUC, respectively, were 36% and 30% higher (200 mg) in patients with mild renal impairment (eCrCL 60 to 89 mL/min), 20% and 73% higher (200 mg) and 3% and 50% higher (400 mg) in patients with moderate renal impairment (eCrCL 30 to 59 mL/min), and 13% higher and 113% higher (400 mg) in patients with severe renal impairment (eCrCL <30 mL/min).
Nakon primjene jednokratne doze lesinurada u osoba s oštećenjem funkcije bubrega, u usporedbi s onima koji imaju normalnu funkciju bubrega, vrijednosti Cmax odnosno AUC lesinurada bile su 36% odnosno 30% veće (200 mg) u bolesnika s blagim oštećenjem funkcije bubrega (eCrCL 60 do 89 ml/min), 20% odnosno 73% veće (200 mg) i 3% odnosno 50% (400 mg) veće u bolesnika s umjerenim oštećenjem funkcije bubrega (eCrCL 30 do 59 ml/min) te 13% više odnosno 113% veće (400 mg) u bolesnika s teškim oštećenjem funkcije bubrega (eCrCL <30 ml/min).
Following administration of a single dose of paracetamol 1000 mg, paracetamol AUC and t1/2 were unchanged whatever the timing of its administration (before or after the lixisenatide injection).
Nakon primjene jednokratne doze paracetamola od 1000 mg AUC i t1/2 paracetamola bili su nepromijenjeni, neovisno o vremenu primjene (prije ili nakon injekcije liksisenatida).
Following administration of a single dose of Prevenar 13 to children (12-59 months) who are considered completely immunised with Prevenar (7-valent) (either 2 or 3 dose primary series plus booster), the proportion achieving serum IgG levels ≥0.35 µg/ml and OPA titres ≥1:8 was at least 90%.
Nakon primjene jedne doze Prevenara 13 djeci (u dobi od 12 do 59 mjeseci) za koju se smatralo da su potpuno dovršila cijepljenje Prevenarom (7-valentnim) (primarna serija s 2 ili 3 doze i docjepljivanje), razine IgG u serumu postigle razinu od ≥0,35 µg/ml, a OPA titar ≥1:8 u najmanje 90% djece.
Following administration of a single oral 750 micrograms dose of [14C]-palonosetron to six healthy subjects, 85 % to 93 % of the total radioactivity was excreted in urine, and 5 % to 8 % was eliminated in feces.
Nakon primjene jedne oralne doze od 750 mikrograma [14C]-palonosetrona u šest zdravih ispitanika, 85% do 93% ukupne radioaktivnosti izlučilo se mokraćom, a 5% do 8% eliminirano je stolicom.
Following administration of a single oral [14C]canagliflozin dose to healthy subjects, 41.5%, 7.0%, and 3.2% of the administered radioactive dose was recovered in faeces as canagliflozin, a hydroxylated metabolite, and an O-glucuronide metabolite, respectively.
Nakon primjene jedne oralne doze [14C]kanagliflozina u zdravih ispitanika, 41,5%; 7,0% i 3,2% primijenjene radioaktivne doze se ponovno našlo u stolici kao kanagliflozin, kao hidroksilirani odnosno O-glukuronidni metabolit.
Following administration of a single oral [14C]canagliflozin dose to healthy subjects, 41.5%, 7.0%, and 3.2% of the administered radioactive dose was recovered in faeces as canagliflozin, a hydroxylated metabolite, and an O-glucuronide metabolite, respectively.
Nakon primjene jedne oralne doze [14C]kanagliflozina u zdravih ispitanika, 41,5%; 7,0% i 3,2% primijenjene radioaktivne doze se ponovno našlo u stolici, kao hidroksilirani odnosno O-glukuronidni metabolit.
Following administration of a single oral dose of 14C-opicapone, the main excretion route of opicapone and its metabolites was faeces, accounting for 58.5% to 76.8% of the administered radioactivity (mean 67.2%).
Nakon primjene jedne peroralne doze 14C-opikapona, glavni put izlučivanja opikapona i njegovih metabolita bio je putem stolice, na što se odnosilo 58,5% do 76,8% primijenjene radioaktivnosti (srednja vrijednost 67,2%).
Following administration of a single oral dose of 750 mg 14C-telaprevir in healthy subjects, 90% of total radioactivity was recovered in faeces, urine and expired air within 96 hours post-dose.
Nakon primjene jednokratne peroralne doze od 750 mg 14C-telaprevira u zdravih ispitanika, 90% ukupne radioaktivnosti otkrilo se u stolici, mokraći i izdahnutom zraku u razdoblju od 96 sati nakon doziranja.
Following administration of a single oral dose of bosutinib 500 mg (therapeutic dose) and bosutinib 500 mg with ketoconazole 400 mg (to achieve supratherapeutic concentrations of bosutinib) in healthy subjects, the upper bound of the one-sided 95% CI around the mean change in QTc was less than 10 ms at all post dose time points, and no AEs suggestive of QTc interval prolongation were observed.
Nakon primjene jedne oralne doze bosutiniba 500 mg (terapijska doza) i bosutiniba 500 mg s ketokonazolom 400 mg (za postizanje supraterapijskih koncentracija bosutiniba) u zdravih ispitanika, gornja granica jednostranog 95%-tnog IP-a oko aritmetičke sredine promjene QTc-a bila je manja od 10 ms u svim vremenskim točkama nakon doze i nisu zapažene nuspojave koje bi upućivale na produljenje QTc intervala.
Following administration of an oral [14C] linagliptin dose to healthy subjects, approximately 85% of the administered radioactivity was eliminated in faeces (80%) or urine (5%) within 4 days of dosing.
Nakon primjene doze oralnog [14C] linagliptina kod zdravih osoba oko 85% primijenjene radioaktivnosti bilo je eliminirano putem fecesa (80%) ili urina (5%) unutar 4 dana od doziranja.
Following administration of an oral [14C] linagliptin dose to healthy subjects, approximately 85% of the administered radioactivity was eliminated in faeces (80%) or urine (5%) within 4 days of dosing.
Nakon primjene doze oralnog [14C] linagliptina kod zdravih osoba, oko 85% primijenjene radioaktivnosti bilo je eliminirano putem fecesa (80%) ili urina (5%) unutar 4 dana od doziranja.
Following administration of an oral [14C]-empagliflozin solution to healthy volunteers, approximately 96% of the drug-related radioactivity was eliminated in faeces (41%) or urine (54%).
Nakon primjene oralne otopine [14C] empagliflozina u zdravih dobrovoljaca, oko 96 % radioaktivnosti povezane s lijekom bilo je izlučeno putem fecesa (41 %) ili urina (54 %).
Following administration of an oral [14C]-empagliflozin solution to healthy volunteers, the red blood cell partitioning was approximately 37% and plasma protein binding was 86%.
Nakon primjene oralne otopine [14C]-empagliflozina u zdravih dobrovoljaca, raspodjela u crvene krvne stanice je iznosila približno 37 %, a vezanje na proteine plazme 86 %.
Following administration of an oral [14C]-empagliflozin solution to healthy volunteers, the red blood cell partitioning was approximately 37% and plasma protein binding was 86%.
Nakon primjene oralne otopine [14C]-empagliflozina u zdravih dobrovoljaca, raspodjela u crvene krvne stanice je iznosila približno 37%, a vezanje na proteine plazme 86%.
Following administration of an oral [14C]sitagliptin dose to healthy subjects, approximately 100 % of the administered radioactivity was eliminated in faeces (13 %) or urine (87 %) within one week of dosing.
Nakon peroralne doze [14C]sitagliptina zdravim ispitanicima približno 100% primijenjene radioaktivnosti eliminiralo se stolicom (13%) ili mokraćom (87%) unutar jednog tjedna od doziranja.
Following administration of an oral [14C]sitagliptin dose to healthy subjects, approximately 100 % of the administered radioactivity was eliminated in faeces (13 %) or urine (87 %) within one week of dosing.
Nakon peroralne primjene doze [14C]sitagliptina zdravim ispitanicima, približno 100% primijenjene radioaktivnosti eliminiralo se stolicom (13%) ili mokraćom (87%) unutar jednog tjedna doziranja.
Following administration of bazedoxifene alone, a linear increase in plasma concentrations for single doses from 0.5 mg up to 120 mg and multiple daily doses from 1 mg to 80 mg was observed.
Nakon primjene samog bazedoksifena, zabilježeno je linearno povećanje koncentracije u plazmi za jednokratnu dozu od 0,5 mg do 120 mg i za višestruku dozu od 1 mg do 80 mg.
Following administration of either a single dose of 0.58 mg of Xiapex to 16 patients with Dupuytren’s contracture, or two concurrent injections of 0.58 mg of Xiapex in the same hand in 12 patients with Dupuytren's contracture, no quantifiable levels of Xiapex were detected in plasma from 5 minutes to 30 days post injection.
Nakon primjene bilo jedne doze od 0,58 mg Xiapexa u 16 bolesnika s Dupuytrenovom kontrakturom, bilo dvije istovremene injekcije Xiapexa u dozi od 0,58 mg u istu šaku u 12 bolesnika s Dupuytrenovom kontrakturom nisu otkrivene mjerljive razine Xiapexa u plazmi u razdoblju od 5 minuta do 30 dana nakon injekcije.
Following administration of food in healthy subjects, peak plasma concentrations were observed approximately 1 hour post-dose for tenofovir alafenamide administered as F/TAF (25 mg) or E/C/F/TAF (10 mg).
Nakon primjene hrane u zdravih ispitanika, vršne koncentracije tenofoviralafenamida u plazmi, primijenjenog kao F/TAF (25 mg) ili E/C/F/TAF (10 mg), bile su opaţene pribliţno 1 sat nakon doziranja.
Following administration of Nimenrix there is a waning of serum bactericidal antibody titres against group A when using human complement in the assay (hSBA) (see section 5.1).
Nakon primjene cjepiva Nimenrix javlja se opadanje titra serumskim baktericidnih protutijela protiv grupe A kada se u testu koristi humani komplement (hSBA – human complement serum bactericidal assay) (vidjeti dio 5.1).
Following administration of Nimenrix there is a waning of serum bactericidal antibody titres against group A when using human complement in the assay (hSBA) (see section 5.1).
Nakon primjene cjepiva Nimenrix javlja se opadanje titra serumskim baktericidnih protutijela protiv grupe kada se u testu koristi humani komplement (hSBA – human complement serum bactericidal assay) (vidjeti dio 5.1).
Following administration of oral 14C- rivastigmine, renal elimination was rapid and essentially complete (>90%) within 24 hours.
Nakon primjene rivastigmina označenog s 14C, eliminacija putem bubrega bila je brza i u osnovi potpuna (>90%) unutar 24 sata.
Following administration of radiolabelled sirolimus, radioactivity is excreted in the milk of lactating rats.
Nakon primjene radioizotopom označenog sirolimusa opažena je radioaktivnost u mlijeku ženki štakora za vrijeme laktacije.
Following administration of SIMBRINZA, small decreases in blood pressure were observed in some patients.
Nakon primjene SIMBRINZE, kod nekih je bolesnika zapaženo manje sniženje krvnog tlaka.
Following administration of SIMBRINZA, small decreases in blood pressure were observed in some patients.
Nakon primjene SIMBRINZE, manje sniženje krvnog tlaka zapaženo je kod nekih bolesnika.
Following administration of single or multiple doses of bosutinib (400 or 500 mg) to humans, the major circulating metabolites appeared to be oxydechlorinated (M2) and N-desmethylated (M5) bosutinib, with bosutinib N-oxide (M6) as a minor circulating metabolite.
Nakon primjene jedne ili višekratnih doza bosutiniba (400 ili 500 mg) u ljudi, čini se da su glavni cirkulirajući metaboliti bili oksidekloriniran (M2) i N-desmetiliran (M5) bosutinib, a bosutinib N-oksid (M6) bio je sporedni cirkulirajući metabolit.
Following administration of tenofovir alafenamide, plasma [14C] -radioactivity showed a time-dependent profile, with tenofovir alafenamide as the most abundant species in the initial few hours and uric acid in the remaining period.
Nakon primjene tenofovir alafenamida, [14C]-radioaktivnost u plazmi pokazala je profil ovisan o vremenu s tenofoviralafenamidom kao najzastupljenijim u prvih nekoliko sati i mokraćnom kiselinom u preostalom razdoblju.
Following administration of the veterinary medicinal product to the animal, adult fleas and larvae are killed and no viable eggs are produced.
Nakon primjene veterinarsko – medicinskog proizvoda na životinji odrasle buhe i larve ugibaju i ne proizvode se larve sposobne za život.
Following administration of the veterinary medicinal product, the adult fleas on the animal are killed, no viable eggs are produced, and larvae (found only in the environment) are also killed.
Nakon primjene veterinarsko – medicinskog proizvoda odrasle buhe na životinji ugibaju, ne proizvode jajašca koja su sposobna za život, a ugibaju i larve (koje se nalaze samo u okolišu).
Following administration of two doses within 60 minutes, Instanyl will lock for a period of 2 hours, from the first dose taken, before another dose can be administered.
Nakon primjene dvije doze unutar 60 minuta Instanyl će se zaključati na razdoblje od 2 sata od prve uzete doze prije nego što se može primijeniti sljedeća doza.
Following administration of Viekirax and dasabuvir
Nakon primjene lijekova Viekirax i dasabuvira
Following administration of Viekirax, the changes in ombitasvir, paritaprevir, and ritonavir exposures in subjects with mild, moderate and severe renal impairment were similar to those observed when Viekirax was administered with dasabuvir, and are not considered to be clinically significant.
Nakon primjene lijeka Viekirax, promjene u izloženosti ombitasviru, paritapreviru i ritonaviru u ispitanika s blagim, umjerenim i teškim oštećenjem bubrežne funkcije bile su slične onima primijećenima kada se Viekirax primjenjivao s dasabuvirom te se ne smatraju klinički značajnima.
Following administration, it is recommended that the intravenous line be flushed with infusion fluid to ensure administration of the complete dose.
Nakon primjene preporučuje se isprati intravensku liniju infuzijskom tekućinom kako bi se osigurala primjena potpune doze.
Following administration, it is recommended that the intravenous line be flushed with infusion fluid to ensure administration of the complete dose.
Nakon primjene, preporučuje se isprati intravensku liniju infuzijsku tekućinom kako bi se osigurala primjena potpune doze.
Following administration, Ovitrelle may interfere for up to ten days with the immunological determination of serum or urinary hCG, potentially leading to a false positive pregnancy test.
Nakon primjene, Ovitrelle može do deset dana interferirati s imunološkim određivanjem serumskog ili mokraćnog hCG te tako uzrokovati lažno pozitivne rezultate.
Following ALIMTA plus cisplatin induction (4 cycles), treatment with ALIMTA was statistically superior to placebo for OS (median 13.9 months versus 11.0 months, hazard ratio = 0.78, 95%CI=0.64-0.96, p=0.0195).
Nakon uvodnog liječenja lijekom ALIMTA i cisplatinom (4 ciklusa), liječenje lijekom ALIMTA bilo je statistički značajno bolje od placeba s obzirom na OS (medijan 13,9 mjeseci naspram 11,0 mjeseci, omjer hazarda= 0,78, 95% CI = 0,64-0,96, p = 0,0195).
Following an 80 mg oral dose of 14C- labeled febuxostat, approximately 49% of the dose was recovered in the urine as unchanged febuxostat (3%), the acyl glucuronide of the active substance (30%), its known oxidative metabolites and their conjugates (13%), and other unknown metabolites (3%).
Nakon peroralno primijenjene doze od 80 mg febuksostata označenog s 14C, oko 49% doze je nađeno u urinu u obliku nepromijenjenog febuksostata (3%), acil glukuronida djelatne tvari (30%), poznatih oksidacijskih metabolita i njihovih konjugata (13%) i drugih nepoznatih metabolita (3%).
Following an intravenous administration of agalsidase beta to adults at doses of 0.3 mg, 1 mg and 3 mg/kg body weight, the AUC values increased more than dose proportional, due to a decrease in clearance, indicating a saturated clearance.
Nakon intravenske primjene agalzidaze beta u odraslih bolesnika u dozama od 0,3 mg, 1 mg i 3 mg/kg tjelesne težine vrijednosti AUC-a su se zbog smanjenja klirensa povećale više nego što je razmjerno dozi, što je ukazalo na zasićeni klirens.
Following an intravenous bolus or subcutaneous injection of a 1.3 mg/m2 dose to patients with multiple myeloma (n=14 in the intravenous group, n=17 in the subcutaneous group), the total systemic exposure after repeat dose administration (AUClast) was equivalent for subcutaneous and intravenous administrations.
Nakon intravenske bolusne ili supkutane injekcije u dozi od 1,3 mg/m2 primjenjene bolesnicima s multiplim mijelomom (n = 14 u intravenskoj skupini, n = 17 u supkutanoj skupini), ukupna sistemska izloženost nakon primjene ponovljenih doza (AUCtrajanja) bila je jednaka za supkutane i intravenske primjene.
Following an intravenous bolus or subcutaneous injection of a 1.3 mg/m2 dose to patients with multiple myeloma (n=14 in the intravenous group, n=17 in the subcutaneous group), the total systemic exposure after repeat dose administration (AUClast) was equivalent for subcutaneous and intravenous administrations.
Nakon intravenske bolusne ili supkutane injekcije u dozi od 1,3 mg/m2 primjenjene bolesnicima s multiplim mijelomom (n=14 u intravenskoj skupini, n=17 u supkutanoj skupini), ukupna sistemska izloženost nakon primjene ponovljenih doza (AUCtrajanja) bila je jednaka za supkutane i intravenske primjene.
Following an oral dose of 14C-labelled azilsartan medoxomil, approximately 55% of radioactivity was recovered in faeces and approximately 42% in urine, with 15% of the dose excreted in urine as azilsartan.
Nakon peroralne doze azilsartanmedoksomila označenog izotopom 14C, približno se 55% radioaktivnosti otkrije u stolici, a približno 42% u mokraći, s time da se 15% doze izluči u mokraći kao azilsartan.
Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in theurine and approximately 46% in the faeces in the 120-hour interval after dosing.
Nakon oralne doze klopidogrela obilježenog s 14C u ljudi približno 50% doze izlučilo se u mokraću, a približno 46% u stolicu u intervalu od 120 sati nakon doziranja.
Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 h.
Nakon oralne doze prividno poluvrijeme eliminacije je približno 6,5 sati.
Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 h.
Nakon peroralne doze prividni poluvijek terminalne eliminacije je približno 6,5 h.
Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 h.
Nakon peroralne doze prividno terminalno poluvrijeme eliminacije iznosi oko 6,5 h.
Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 h.
Nakon peroralne doze, prividni terminalni poluvijek eliminacije iz tijela je približno 6,5 sati.
Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 h.
Nakon peroralne doze, prividno poluvrijeme eliminacije iz tijela je približno 6,5 sati.
Following ascending single oral doses (25-675 mg migalastat hydrochloride), no trends were found for clearance, CL/F).
Nakon povećavanja jednokratnih oralnih doza (25 – 675 mg migalastatklorida) nije primijećen nikakav trend za klirens CL/F.
Following assessment of this PSUR (reporting period 01 September 2014 –31 August 2015) the PRAC concluded that Acquired Fanconi syndrome (FS) should be included in the section 4.8 of the SmPC with the frequency ‘rare’.
Nakon ocjene ovog PSUR-a (izvještajno razdoblje od 01. rujna 2014 – 31. kolovoza 2015) PRAC je donio zaključak da je stečeni Fanconijev sindrom (FS) potrebno uvrstiti u dio 4.8 SmPC-a s učestalošću „rijetko“.
Following blood tests, your doctor has decided you need Aranesp as your haemoglobin level is 10 g/dl or less.
Nakon krvnih pretraga, Vaš liječnik je odlučio da trebate primjenjivati Aranesp kada je vrijednost Vašeg hemoglobina 10 g/dl ili niža.
Following booster vaccination, children > 12 months of age are more likely to experience injection site reactions compared to the rates observed in infants during the primary series with Synflorix.
Nakon dodatnog cijepljenja veća je vjerojatnost da će djeca u dobi >12 mjeseci imati reakcije na mjestu injiciranja u usporedbi sa stopama primijećenima u dojenčadi tijekom primarne serije cijepljenja cjepivom Synflorix.
Following booster vaccination, the most common adverse reactions were pain at the injection site and irritability, which occurred at approximately 51% and 53% respectively.
Nakon dodatnog cijepljenja najčešće nuspojave bile su bol na mjestu injekcije i razdražljivost, a javile su se u približno 51% odnosno 53% slučajeva.
Following careful benefit/risk assessment, a decision should be made to discontinue either breast-feeding or treatment with Mimpara.
Odluku o prekidu dojenja ili liječenja Mimparom treba donijeti na osnovi pomne procjene koristi i rizika.
Following catch-up vaccination in children 12 to 23 months of age, urticaria was reported more frequently (uncommon) compared to the rates observed in infants during primary and booster vaccination.
Nakon naknadne provedbe cijepljenja zbog propuštene ili odgođene uobičajene vakcinacije u djece u dobi od 12 do 23 mjeseca, urtikarija je prijavljena s većom učestalošću (manje često) u usporedbi sa stopama primijećenima u dojenčadi tijekom primarnog cijepljenja i docjepljivanja.
Following cessation of treatment, signs of adrenal insufficiency extending to adrenocortical atrophy can arise and this may render the animal unable to deal adequately with stressful situations.
Nakon prestanka liječenja, mogu se pojaviti znakovi insuficijencije nadbubrežne žlijezde koji se proširuju na adrenokortikalnu atrofiju te to može učiniti životinju nesposobnom da se primjereno nosi sa stresnim situacijama.
Following co-administration, increased incidences of transposed umbilical artery and incomplete ossification of occipital bone were found in rats at doses associated with known glucocorticoid- induced abnormalities.
Nakon istovremene primjene, povećana incidencija transpozicije umbilikalne arterije i nepotpune osifikacije okcipitalne kosti pronađena je u štakora pri dozama povezanima s poznatim abnormalnostima koje izazivaju glukokortikoidi.